FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Lentini Renee 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2021 

3. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]
(Last)       (First)       (Middle)
830 WINTER STREET
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
V.P.-Fin., Prin. Acctg. Off. /
(Street)
WALTHAM, MA 02451      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  12148  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy)  7/22/2012 (1) 7/22/2021  Common Stock  9000  $15.20  D   
Stock Option (Right to buy)  7/20/2013 (1) 7/20/2022  Common Stock  9000  $15.83  D   
Stock Option (Right to buy)  7/16/2014 (1) 7/16/2023  Common Stock  9000  $19.02  D   
Stock Option (Right to buy)  7/17/2015 (1) 7/17/2024  Common Stock  9000  $10.79  D   
Stock Option (Right to buy)  7/13/2016 (1) 7/13/2025  Common Stock  8250  $16.72  D   
Stock Option (Right to buy)  7/18/2017 (1) 7/18/2026  Common Stock  11500  $3.05  D   
Stock Option (Right to buy)  9/30/2017 (1) 9/30/2026  Common Stock  19000  $2.68  D   
Stock Option (Right to buy)  2/21/2018 (1) 2/21/2027  Common Stock  6000  $2.47  D   
Stock Option (Right to buy)  2/15/2019 (2) 2/15/2028  Common Stock  23000  $10.65  D   
Stock Option (Right to buy)  1/31/2020 (2) 1/31/2029  Common Stock  36400  $5.25  D   
Stock Option (Right to buy)  7/18/2020 (3) 7/18/2029  Common Stock  69000  $2.31  D   
Stock Option (Right to buy)  2/7/2021 (3) 2/7/2030  Common Stock  52440  $4.55  D   

Explanation of Responses:
(1)  All options are exercisable as of the filing date of this Form 3.
(2)  Exercisable in three equal installments over three years starting on the first year anniversary of the grant.
(3)  25% of the options are exercisable on the first year anniversary of the grant and the balance is exercisable in twelve equal installments of 6.25%, quarterly over the following three years starting one quarter after the first year anniversary.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Lentini Renee
830 WINTER STREET
WALTHAM, MA 02451


V.P.-Fin., Prin. Acctg. Off.

Signatures
/s/ Renee Lentini 1/11/2021
**Signature of Reporting Person Date